If participant is enrolled in Part 2, participant will receive alpelisib and enzalutamide at the highest dose that was tolerated in Part 1. If participant is taking part in Part 1 and is receiving a dose lower than what will be given to Part 2 participants, participant's dose may be changed to receive the highest tolerable dose.